Investors should continue to invest in defensive stocks in strong dividend sectors like telecommunications, technology and pharmaceuticals, said Willem Nabarro, head of European equities for Asia at Exane-BNP Paribas on Tuesday.
Well, that didn't take long. It's only the first business day of the new year and big pharma's already gettin' down to business. Novartis is buying the rest of its Swiss neighbor Alcon for a cool $38.5 billion.
Most European exchanges are up about 1 percent (but China closed down 1 percent), commodities are strong, with metals up 2 percent across the board. Oil over $80.
U.S. stock markets opened higher on Christmas Eve, as reports showed that durable goods orders rose and jobless claims fell. Art Cashin, director of floor operations at UBS Financial Services, offered CNBC his insights on this shortened trading day.
Eli Lilly did the expected today, but investors were hoping for more. Bears mauled the drug maker, unloading shares and snapping up puts, after management failed to address concerns about major patent expirations beginning in 2011.
Did you see the cover of the latest Barron’s? The one that says to move into high yielding stocks? It's exactly what we said to do, about a month ago!
Although most of market is moving sideways, we've spotted some stocks that have continued their upward trend.
For the second time in three weeks I'm at a flu vaccine manufacturing plant today. Construction isn't finished on the Novartis site yet, but nonetheless they're doing the formal ribbon-cutting ceremony here in Holly Springs, NC this afternoon.
Cramer makes the call on viewers' favorite stocks.
The Federal Reserve is monitoring the declining value of the dollar closely as part of its commitment to both jobs growth and price stability, said Fed Chairman Ben Bernanke on Monday. Art Cashin, director of floor operations at UBS Financial Services, shared his insights on the Fed and the markets.
U.S. producer prices rose more slowly than expected in October despite a rebound in food and energy costs, according to a report on Tuesday. Bruce Kasman, chief U.S. economist at JPMorgan, shared his view.
Many analysts, lobbyists and industry executives have been saying for months that healthcare reform would probably end up being a net positive for the drug companies.
You know that Tim Seymour is bullish on China but now he’s got three new reasons to get long. Should you follow any of them?
GlaxoSmithKline is one of the handful of drug companies on the front lines of the fight against the flu. In fact, it is the only company that has products on both sides. GSK makes a vaccine and an antiviral. In the third quarter, GSK today reported that it sold nearly $300 million worth of the inhalable flu-fighter Relenza. That’s a more than 10-fold increase from a year ago. And CEO Andrew Witty reportedly forecast around $1.6 billion worth of flu shot sales in the fourth quarter.
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.
Swiss drug giant Novartis says it has redeployed 300 workers from other divisions into its vaccines unit to meet what Chairman and CEO Dr. Daniel Vasella calls the "huge demand" for H1N1 shots.
Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.
Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.
Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices.
With Amgen dropping after hours and Merck, Celgene and others reporting earnings on Thursday, how should you game health care?